-
Product Insights
NewMild Cognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Mild Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety, and apathy. Risk factors include diabetes, high blood pressure, depression, smoking, and elevated cholesterol. The Mild...
-
Product Insights
NewDementia Associated With Alzheimer’s Disease – Drugs In Development, 2024
Empower your strategies with our Dementia Associated With Alzheimer's Disease – Drugs In Development, 2024 report and make more profitable business decisions. Alzheimer's disease (AD) is the most common cause of dementia. AD is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and changes in behavior and thinking skills that interfere with daily functioning. Early symptoms may include mild forgetfulness, difficulty recalling recent events or information, and trouble with problem-solving or complex tasks. One of the hallmark features of...
-
Product Insights
NewCognitive Impairment – Drugs In Development, 2024
Empower your strategies with our Cognitive Impairment – Drugs In Development, 2024 report and make more profitable business decisions. Cognitive impairment is a condition characterized by a decline in cognitive functions, such as memory, attention, and problem-solving skills. It can range from mild to severe and may result from various causes, including aging, neurodegenerative diseases (like Alzheimer's), vascular disorders, traumatic brain injuries, infections, medication side effects, mental health issues, nutritional deficiencies, or environmental factors. Symptoms can include memory loss, confusion, difficulty...
-
Product Insights
NewAcute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024
Empower your strategies with our Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024 report and make more profitable business decisions. Acute renal failure occurs when the kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics. The Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewHuntington Disease – Drugs In Development, 2024
Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions. Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varoglutamstat in Mild Cognitive Impairment
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Varoglutamstat in Mild Cognitive ImpairmentDrug Details:PQ-912 is under development for the treatment of early stage mild...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DX-126262 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DX-126262 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DX-126262 in Bladder Cancer Drug Details:DX-126262 is under development for the treatment of...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Track & Monitor
Biosimilars in Pharmaceuticals: Neuro-degenerative receptor binding drug compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Neuro-degenerative receptor binding drug compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...